Immune checkpoint inhibitors (ICIs), which target immunosuppressive receptors such as CTLA-4 and PD-1 to improve the cytotoxicity and proliferative potential of tumor-infiltrating lymphocytes (TILs), are among the most effective immunotherapeutics [36]. This evidence concerns the gene CTLA4 and neoplasm.